2019
HIV RNA, CD4+ Percentage, and Risk of Hepatocellular Carcinoma by Cirrhosis Status
Torgersen J, Kallan MJ, Carbonari DM, Park LS, Mehta RL, D’Addeo K, Tate JP, Lim JK, Goetz MB, Rodriguez-Barradas MC, Gibert CL, Bräu N, Brown ST, Roy JA, Taddei TH, Justice AC, Re V. HIV RNA, CD4+ Percentage, and Risk of Hepatocellular Carcinoma by Cirrhosis Status. Journal Of The National Cancer Institute 2019, 112: 747-755. PMID: 31687755, PMCID: PMC7357318, DOI: 10.1093/jnci/djz214.Peer-Reviewed Original ResearchConceptsRisk of HCCHigher HIV RNAHCC risk factorsHIV RNAHIV viremiaHepatocellular carcinomaBaseline cirrhosisCirrhosis statusCohort studyRisk factorsCell percentageVeterans Aging Cohort StudyDevelopment of HCCCurrent HIV RNADetectable HIV viremiaHepatitis C coinfectionAging Cohort StudyDiagnosis of cirrhosisLonger durationDetectable HIVLow CD4C coinfectionCurrent CD4Hazard ratioCancer RegistryAssociation of Immunosuppression and Human Immunodeficiency Virus (HIV) Viremia With Anal Cancer Risk in Persons Living With HIV in the United States and Canada
Hernández-Ramírez RU, Qin L, Lin H, Leyden W, Neugebauer RS, Althoff KN, Hessol NA, Achenbach CJ, Brooks JT, Gill MJ, Grover S, Horberg MA, Li J, Mathews WC, Mayor AM, Patel P, Rabkin CS, Rachlis A, Justice AC, Moore RD, Engels EA, Silverberg MJ, Dubrow R, Benson C, Bosch R, Kirk G, Mayer K, Grasso C, Hogg R, Harrigan P, Montaner J, Yip B, Zhu J, Salters K, Gabler K, Buchacz K, Li J, Gebo K, Moore R, Moore R, Rodriguez B, Horberg M, Silverberg M, Thorne J, Rabkin C, Margolick J, Jacobson L, D’Souza G, Klein M, Kroch A, Burchell A, Betts A, Lindsay J, Hunter-Mellado R, Mayor A, Gill M, Deeks S, Martin J, Li J, Brooks J, Saag M, Mugavero M, Willig J, Mathews W, Eron J, Napravnik S, Kitahata M, Crane H, Drozd D, Sterling T, Haas D, Rebeiro P, Turner M, Justice A, Dubrow R, Fiellin D, Gange S, Anastos K, Moore R, Saag M, Gange S, Kitahata M, Althoff K, Horberg M, Klein M, McKaig R, Freeman A, Moore R, Freeman A, Kitahata M, Van Rompaey S, Crane H, Drozd D, Morton L, McReynolds J, Lober W, Gange S, Althoff K, Lee J, You B, Hogan B, Zhang J, Jing J, Humes E, Coburn S. Association of Immunosuppression and Human Immunodeficiency Virus (HIV) Viremia With Anal Cancer Risk in Persons Living With HIV in the United States and Canada. Clinical Infectious Diseases 2019, 70: 1176-1185. PMID: 31044245, PMCID: PMC7319056, DOI: 10.1093/cid/ciz329.Peer-Reviewed Original ResearchConceptsAnal cancer riskHIV RNA measuresCancer riskPeak CD4North American AIDS Cohort CollaborationRNA measuresHIV-1 RNA levelsHuman immunodeficiency virus (HIV) viremiaOncogenic human papillomavirus (HPV) infectionAnal cancer developmentAssociation of immunosuppressionTime-updated CD4T-cell countsHuman papillomavirus infectionHuman immunodeficiency virusCohort CollaborationPapillomavirus infectionImmunodeficiency virusImmunoregulatory controlCD4Cox modelCancer promotionUseful markerCancer developmentRNA levels
2016
Baseline, Time-Updated, and Cumulative HIV Care Metrics for Predicting Acute Myocardial Infarction and All-Cause Mortality
Salinas JL, Rentsch C, Marconi VC, Tate J, Budoff M, Butt AA, Freiberg MS, Gibert CL, Goetz MB, Leaf D, Rodriguez-Barradas MC, Justice AC, Rimland D. Baseline, Time-Updated, and Cumulative HIV Care Metrics for Predicting Acute Myocardial Infarction and All-Cause Mortality. Clinical Infectious Diseases 2016, 63: 1423-1430. PMID: 27539575, PMCID: PMC5106607, DOI: 10.1093/cid/ciw564.Peer-Reviewed Original ResearchConceptsAcute myocardial infarctionIncident acute myocardial infarctionVeterans Aging Cohort StudyCombination antiretroviral therapyCardiovascular risk factorsHIV-1 RNAVACS IndexHazard ratioMyocardial infarctionRisk factorsMultivariable proportional hazards modelsVACS Index scoreLast clinic visitAging Cohort StudyHuman immunodeficiency virusProportional hazards modelCART initiationAntiretroviral therapyCause mortalityCD4 countClinic visitsCohort studyOrgan injuryPrimary outcomeImmunodeficiency virusIsolated Hepatitis B Core Antibody is Associated With Advanced Hepatic Fibrosis in HIV/HCV Infection But Not in HIV Infection Alone
Bhattacharya D, Tseng CH, Tate JP, Re V, Gibert CL, Butt AA, Brown ST, Lim JK, Rodriguez-Barradas MC, Rimland D, Kaufman E, Justice AC, Goetz MB. Isolated Hepatitis B Core Antibody is Associated With Advanced Hepatic Fibrosis in HIV/HCV Infection But Not in HIV Infection Alone. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2016, 72: e14-e17. PMID: 26829660, PMCID: PMC4837046, DOI: 10.1097/qai.0000000000000941.Peer-Reviewed Original Research
2013
Hepatitis C Viremia and the Risk of Chronic Kidney Disease in HIV-Infected Individuals
Lucas G, Jing Y, Sulkowski M, Abraham A, Estrella M, Atta M, Fine D, Klein M, Silverberg M, Gill M, Moore R, Gebo K, Sterling T, Butt A, for the NA-ACCORD of the IeDEA, Kirk G, Benson C, Bosch R, Collier A, Boswell S, Grasso C, Mayer K, Hogg R, Harrigan R, Montaner J, Cescon A, Brooks J, Buchacz K, Gebo K, Moore R, Carey J, Rodriguez B, Horberg M, Silverberg M, Horberg M, Thorne J, Goedert J, Jacobson L, Klein M, Rourke S, Burchell A, Rachlis A, Rico P, Hunter-Mellado R, Mayor A, Gill M, Deeks S, Martin J, Patel P, Brooks J, Saag M, Mugavero M, Willig J, Eron J, Napravnik S, Kitahata M, Crane H, Justice A, Dubrow R, Fiellin D, Sterling T, Haas D, Bebawy S, Turner M, Gange S, Anastos K, Moore R, Saag M, Gange S, Kitahata M, McKaig R, Justice A, Freeman A, Moore R, Freeman A, Lent C, Kitahata M, Van Rompaey S, Crane H, Webster E, Morton L, Simon B, Gange S, Althoff K, Abraham A, Lau B, Zhang J, Jing J, Golub E, Modur S, Hanna D, Rebeiro P, Wong C, Mendes A. Hepatitis C Viremia and the Risk of Chronic Kidney Disease in HIV-Infected Individuals. The Journal Of Infectious Diseases 2013, 208: 1240-1249. PMID: 23904290, PMCID: PMC3778973, DOI: 10.1093/infdis/jit373.Peer-Reviewed Original ResearchConceptsStage 3 CKDStage 5 CKDProgressive CKDAviremic subjectsHazard ratioGlomerular filtration rate decreaseChronic kidney disease riskHepatitis C virus replicationHCV seronegative subjectsHCV viremic subjectsAdjusted hazard ratioChronic kidney diseaseHepatitis C viremiaKidney disease riskConfidence intervalsC virus replicationAdvanced CKDAviremic individualsCKD incidenceHCV-viremicSeronegative subjectsC viremiaViremic subjectsKidney diseaseCKD
2004
Effect of Persistent Moderate Viremia on Disease Progression During HIV Therapy
Raffanti SP, Fusco JS, Sherrill BH, Hansen NI, Justice AC, D’Aquila R, Mangialardi WJ, Fusco GP. Effect of Persistent Moderate Viremia on Disease Progression During HIV Therapy. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2004, 37: 1147-1154. PMID: 15319674, DOI: 10.1097/01.qai.0000136738.24090.d0.Peer-Reviewed Original ResearchConceptsHIV-1 RNA levelsCopies/mLBaseline HIV-1 RNA levelsNew AIDSCopies/Moderate viremiaRNA levelsPlasma HIV-1 RNAAIDS-defining diagnosisAntiretroviral therapy historyActive antiretroviral therapyUnited States cohortHIV-1 RNACells/Proportional hazards modelCD4 count changesImmunologic deteriorationAntiretroviral therapyCD4 countPrior AIDSUndetectable viremiaViral suppressionImmunologic statusHIV infectionClinical benefit